Cargando…

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients

BACKGROUND: High grade serous ovarian cancer (HGSOC) is the most common subtype of ovarian cancer. Although platinum-based chemotherapy has been the cornerstone for HGSOC treatment, nearly 25% of patients would have less than 6 months of interval since the last platinum chemotherapy, referred to as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuan, Zhang, Xiaolan, Gao, Yan, Shang, Chunliang, Yu, Bo, Wang, Tongxia, Su, Junyan, Huang, Cuiyu, Wu, Yu, Guo, Hongyan, Ha, Chunfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977004/ https://www.ncbi.nlm.nih.gov/pubmed/33747898 http://dx.doi.org/10.3389/fonc.2020.625866

Ejemplares similares

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer
por: James, Nicole E., et al.
Publicado: (2021)

Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients
por: Romani, Chiara, et al.
Publicado: (2020)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma
por: Liu, Gang, et al.
Publicado: (2018)

Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
por: Reid, Brett M., et al.
Publicado: (2021)

Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis
por: Li, Yuan, et al.
Publicado: (2023)

A New Spontaneously Transformed Syngeneic Model of High-Grade Serous Ovarian Cancer with a Tumor-Initiating Cell Population
por: McCloskey, Curtis W., et al.
Publicado: (2014)

Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer
por: Koc, Zeynep C., et al.
Publicado: (2023)

Comparative analysis between high-grade serous ovarian cancer and healthy ovarian tissues using single-cell RNA sequencing
por: Zhang, Xiao, et al.
Publicado: (2023)

High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis
por: Guo, Wenwen, et al.
Publicado: (2021)

Advances in Tumor Screening, Imaging, and Avatar Technologies for High-Grade Serous Ovarian Cancer
por: Ohman, Anders W., et al.
Publicado: (2014)

High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer
por: Song, Li, et al.
Publicado: (2019)

Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
por: Heredia-Soto, Victoria, et al.
Publicado: (2022)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
por: Mairinger, Fabian, et al.
Publicado: (2019)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer
por: Dai, Danian, et al.
Publicado: (2021)

Stage, treatment and survival of low‐grade serous ovarian carcinoma in the Netherlands: A nationwide study
por: De Decker, Koen, et al.
Publicado: (2023)

Nomograms of Combining MRI Multisequences Radiomics and Clinical Factors for Differentiating High-Grade From Low-Grade Serous Ovarian Carcinoma
por: Li, Cuiping, et al.
Publicado: (2022)

Construction of a prognostic signature for serous ovarian cancer based on lactate metabolism-related genes
por: Xiang, Jiangdong, et al.
Publicado: (2022)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases
por: Pejovic, Tanja, et al.
Publicado: (2022)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
por: Rundo, Leonardo, et al.
Publicado: (2022)

A Computed Tomography-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study
por: Wei, Wei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_24pe5irbe295v37391a0qs0h3a